Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer
| Autor: | Lei Wang, Huixing Wang, Guangjun Zheng, Qiang Cao, Yuanjie Niu, Xiaodong Huo, Junjie Wang, Shude Chai, Kuo Yang, Zuncheng Zhang, Bin Huo, Haitao Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_treatment
Brachytherapy lcsh:Medicine 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine medicine Radiology Nuclear Medicine and imaging Stage (cooking) Lung cancer Original Paper Chemotherapy business.industry lcsh:R Combination chemotherapy Seed Implantation medicine.disease Gemcitabine 125I Radiation therapy lung cancer Oncology 030220 oncology & carcinogenesis non-small cell lung carcinoma (NSCLC) Nuclear medicine business medicine.drug |
| Zdroj: | Journal of Contemporary Brachytherapy, Vol 9, Iss 6, Pp 527-534 (2017) Journal of Contemporary Brachytherapy |
| ISSN: | 2081-2841 |
| Popis: | Purpose : We investigated the role of computed tomography (CT)-guided Iodine-125 ( 125 I) seed implantation in combination with chemotherapy for the treatment of stage III non-small cell lung carcinoma (NSCLC). Material and methods : The data from 182 patients with stage III NSCLC who were treated with radioactive 125 I seed implantation between June 2002 and June 2009, and who received sequential platinum-based combination chemotherapy using the most common combination of platinum and gemcitabine, were retrospectively reviewed. The 182 patients received a prescribed dose of 110.0 Gy, with a median radioactivity of 0.70 mCi (range, 0.64-0.78 mCi, 2.37-3.26 × 107 Bq). The median number of 125 I seeds was 38 pellets (range, 6-105 pellets). The median post-operation dose covering 100% of the target volume (D 100 ) was 94.5 Gy (range, 54.6-125.5 Gy). The median D 90 was 143.0 Gy (range, 121.6-184.0). Results : The 1-, 3-, and 5-year overall survival rates were 83.35%, 25.57%, and 11.34%, respectively; the median survival time was 24.76 months. At 1, 3, and 5 years, the local control rates were 92.01%, 86.51%, and 76.45%, respectively; the median local control time was 25.28 months. For patients with stage IIIA and IIIB NSCLC, the median survival times were 26.67 and 24.59 months, respectively (p = 0.2). Pre-treatment hemoglobin level, tumor volume, and postoperative D 100 were significantly associated with survival. A total of 24 patients experienced pneumothorax (incidence rate, 13.20%), and 17 patients experienced hemothorax (incidence rate, 5.0%). Conclusions : CT-guided 125 I seed implantation combined with chemotherapy is an effective, minimally invasive method for the treatment of stage III NSCLC. Furthermore, hemoglobin levels before treatment, D 100 , and the maximum diameter of the tumor may be prognostic factors in patients with NSCLC treated sequentially with radiotherapy and chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|